Clinical Trial Update: Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sacituzumab tirumotecan (SKB264) in combination with toripalimab for initially unresectable stage III non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sacituzumab tirumotecan (SKB264)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non Small Cell Lung Cancer (Stage III) | Phase 2 | Status: NOT_YET_RECRUITING